We Build. We Validate. We Deliver. ResearchDx offers expertise as an integrated start-to-finish partner for Diagnostic Development. Clear Strategic Guidance ResearchDx supports all types of regulatory submissions. Identify the BEST Solution From Orthogonal method validation, Multi-site Reproducibility, HEAD-TO-HEAD comparison with
1Diagnostic Development for Precision Medicine
From NGS, RT qPCR, ddPCR to ELISA, Flow and IHC, we bring you the BEST solution to fit your needs.2Regulatory Guidance
From Analytic Validation, IDE, 510(k), De Novo, to single site or Full PMA and BIMO. 3Assay Comparison
the gold standard, to studies designed to highlight technology/method advantages.
POSITIVE RESULTS FOR SUBB2M BREAST CANCER TEST
This text has been reposted from an earlier press release from INOVIQ Limited. Melbourne, Australia, 8 February 2023: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) is pleased to announce positive results from an independent retrospective case-control study to evaluate the performance of its SubB2M-CA15.3 breast cancer test across all stages of breast cancer. Read full […]
Read More